Welcome to our dedicated page for Ligand Pharma news (Ticker: LGND), a resource for investors and traders seeking the latest updates and insights on Ligand Pharma stock.
Ligand Pharmaceuticals Inc. (NASDAQ: LGND) is a biopharmaceutical company that regularly issues news about its royalty portfolio, technology platforms and capital deployment. The company describes its model as enabling the clinical development of high‑value medicines by providing financing, licensing its technologies, or both, and this approach is reflected in its press releases and investor communications.
News about Ligand often covers financial results and guidance, including updates on total core revenue, royalty revenue, Captisol sales, contract revenue and non‑GAAP measures such as core adjusted earnings per diluted share. The company’s announcements highlight how royalty revenue from partnered products such as Filspari, Ohtuvayre, Capvaxive, Qarziba and Zelsuvmi contributes to its outlook, as well as how deployable capital and new royalty investments are expected to influence long‑term royalty receipts.
Investors following LGND news will also see updates on Ligand’s technology platforms and partner programs. Releases describe Captisol‑enabled approvals like Lasix ONYU, developments in programs such as Qtorin rapamycin, and clinical or regulatory milestones reported by partners that may affect Ligand’s royalty streams. In addition, the company reports on financing transactions, including convertible senior notes offerings and amendments to its credit agreement, which provide context on how Ligand funds royalty acquisitions and other strategic investments.
Corporate events such as Investor Day presentations and participation in healthcare and biopharma conferences are another recurring theme in Ligand’s news flow. These events typically feature discussions of strategy, investment activity, the royalty portfolio and long‑term financial outlook. For investors and observers, the LGND news page offers a centralized view of how Ligand’s royalty‑focused business model, technology licensing and capital allocation decisions evolve over time.
Ligand Pharmaceuticals (NASDAQ: LGND) announced an expansion of its collaboration with GlaxoSmithKline (GSK), leveraging Icagen's ion-channel discovery technology for neurological diseases.
Ligand will receive an upfront payment of $10 million, with potential development and regulatory milestones up to $67.5 million.
The deal includes commercial milestone payments of up to $60 million and tiered royalties on net sales of any drugs commercialized by GSK.
Ligand Pharmaceuticals (NASDAQ: LGND) reported strong Q3 2021 results with total revenues of $64.8 million, a significant increase from $41.8 million in Q3 2020. Royalties rose to $15.6 million, up from $9.0 million, driven by products like Kyprolis and Evomela. Captisol sales surged to $35.1 million, primarily due to COVID-19 treatment demand. Net income was $13.7 million or $0.80 per share compared to a loss of $6.7 million in the same quarter last year. Ligand is also planning a split into two distinct companies to enhance focus on its OmniAb platform and royalty business, aiming for continued growth.
Ligand Pharmaceuticals (NASDAQ: LGND) has announced plans to separate into two publicly traded companies: one focused on the OmniAb business and another on core royalties and technologies. This move aims to enhance operational focus and attract investment. CEO John Higgins highlighted a successful year for OmniAb, marked by regulatory approvals of its derived antibodies. An IPO for OmniAb shares is under consideration, potentially distributing less than 20% to shareholders in a tax-efficient manner. However, no specific course of action has been approved by the board yet.
Ligand Pharmaceuticals (NASDAQ: LGND) will announce its financial results for the three and nine months ending September 30, 2021 on November 9, 2021, after market close. A conference call will be held on the same day at 4:30 p.m. Eastern time, featuring CEO John Higgins, President and COO Matt Foehr, and Executive VP and CFO Matt Korenberg. Ligand focuses on drug discovery and partnerships to create revenue streams, leveraging patented technologies like OmniAb® and Captisol®.
Ligand Pharmaceuticals (NASDAQ: LGND) announced a collaboration with China Resources Double-Crane Pharmaceutical (CRDC) to develop a novel oral COVID-19 antiviral using Ligand's BEPro technology. Ligand will receive an upfront payment, potential clinical milestone payments, and tiered royalties on net sales, while CRDC bears all program costs. The BEPro technology is patented and aims to improve the pharmacokinetics of antiviral compounds, showing favorable profiles in preclinical studies. The deal signals a continued effort to monetize Ligand's innovations, enhancing shareholder value.
Ligand Pharmaceuticals (NASDAQ: LGND) announced that its partner, Gloria Biosciences, has received approval from the National Medical Products Administration (NMPA) in China for zimberelimab (GLS-010), an anti-PD-1 monoclonal antibody, for treating recurrent or refractory classical Hodgkin's lymphoma (cHL). This marks the first regulatory approval for an OmniAb-derived antibody and follows promising clinical data, including a 90.6% overall response rate in a Phase 2 study. Ligand is entitled to royalties on future sales of zimberelimab, enhancing its revenue potential.
Ligand Pharmaceuticals (NASDAQ: LGND) announced positive interim results from the pivotal Phase 3 PROTECT Study of sparsentan, a treatment for IgA nephropathy (IgAN). The study showed a statistically significant reduction in proteinuria after 36 weeks, with sparsentan achieving a 49.8% mean decrease compared to 15.1% for irbesartan (p0.0001). Ligand is set to receive a $5.9 million milestone upon NDA submission by Travere, the partner company. Sparsentan's promising data could lead to accelerated approval in the U.S. and conditional marketing authorization in Europe.
Ligand Pharmaceuticals (NASDAQ: LGND) reported strong Q2 2021 financial results, with total revenues of $84.7 million, up from $41.4 million year-over-year. Key contributors included $62.5 million in Captisol sales, mainly for remdesivir, and contract revenue of $13.6 million. Net income rose to $30.7 million ($1.79 per diluted share), aided by a $34.1 million non-cash valuation adjustment. However, the company lowered full-year revenue guidance to $265-$275 million due to reduced Captisol demand. Ligand anticipates multiple regulatory drug approvals this year, enhancing revenue streams in 2022 and beyond.
Landing AI has signed a software licensing agreement with Ligand Pharmaceuticals (NASDAQ: LGND) to integrate LandingLens into Ligand's OmniAb and xPloration antibody discovery platforms. This AI-driven technology enhances high-throughput B cell screening accuracy, potentially accelerating antibody yield production. Both companies emphasize creating accurate datasets for continuous AI system improvement. Ligand aims to leverage this partnership to strengthen its pharmaceutical technology and improve drug discovery efficiencies.
Ligand Pharmaceuticals (NASDAQ: LGND) announces that Jazz Pharmaceuticals (NASDAQ: JAZZ) has launched Rylaze™ (asparaginase erwinia chrysanthemi), approved by the FDA on June 30, 2021. This drug offers a therapeutic option for patients with acute lymphoblastic leukemia or lymphoblastic lymphoma who are hypersensitive to E. coli-derived asparaginase. Ligand received $2 million upon the FDA's review and will earn $5 million at the first commercial sale, plus up to $155.5 million in milestone payments and royalties based on global sales, demonstrating a strong partnership with Jazz Pharmaceuticals.